EU Committee Nod For Lilly's Ixekizumab In Psoriasis
This article was originally published in Scrip
Executive Summary
Eli Lilly & Co. is one step closer to challenging Novartis's front-running anti-IL-17A agent Cosentyx (secukizumab), having received a positive recommendation from the EU's CHMP for its similar product ixekizumab in psoriasis.